LY2189102 is a humanized monoclonal antibody inhibitor targeting interleukin-1beta (IL-1beta). LY2189102 is promising for research of type 2 diabetes[1].
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
